Phase I Study of Belinostat (PXD-101) and Velcade (Bortezomib) in Relapsed or Refractory Acute Leukemia/ Myelodysplastic Syndrome
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2016
At a glance
- Drugs Belinostat (Primary) ; Bortezomib
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 13 Apr 2016 Status changed from active, no longer recruiting to completed.
- 11 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 28 Jun 2015 Planned End Date changed from 1 May 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.